In vitro metabolism and non-clinical adme studies IDIQ contract. POP 9/27/21-9/26/26. NTE $3.5 million. First task order 01 obligated in the amount of $89,708.00. POP for the to 01 9/27/21-9/26/22
Ended Indefinite Delivery Contract Awarded Last action
- Contract number
- 75N95021D00025
- Awardee
-
Sri International UEI SRG2J1WS9X63
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Task orders
- 0
Award facts
- Opportunity
-
- In Vitro Metabolism and Non-Clinical ADME Studies Pre-Solicitation · N01DA218957 · Posted Sep 29, 2020
- Last date to order 100% complete
- IDV ceiling
- $342,897.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Negotiated Proposal / Quote
- Pricing
- Order Dependent (IDV only)
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
About this IDV
This Indefinite Delivery Contract (IDC) is a single-award contract awarded by the National Institute on Drug Abuse (NIDA), a civilian agency, to Sri International, a non-profit research and development organization. The contract, valued at a ceiling of $342,897, is for the provision of IN VITRO METABOLISM AND NON-CLINICAL ADME STUDIES over a 5-year period of performance from September 27, 2021 to April 25, 2025. The contract was not set aside for any specific business size or socioeconomic category.
The original solicitation, a pre-solicitation notice, sought information on the availability and capabilities of qualified small businesses and other-than-small businesses to perform this work, which falls under NAICS code 541712 - Research and Development in the Physical, Engineering, and Life Sciences. The first task order, valued at $89,708, has a period of performance from September 27, 2021 to September 26, 2022. The overall IDC has a not-to-exceed ceiling of $3.5 million. Through this contract, NIDA aims to efficiently access Sri International's specialized technical capabilities in advanced scientific research and development to support its mission and programs.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | $0 | |
| Exercise an Option | $25,538 | |
| Funding Only Action | $29,161 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $32,796 | |
| Funding Only Action | $136,939 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $28,755 | |
| Other Administrative Action | $0 | |
| Original award | $89,708 |
Quick answers
Who was awarded contract 75N95021D00025?
75N95021D00025 was awarded to Sri International by National Institute on Drug Abuse (National Institutes of Health) on September 27, 2021.
How much is contract 75N95021D00025 worth?
75N95021D00025's own ceiling is $342,897.
Who can order from contract 75N95021D00025?
75N95021D00025 is a single award indefinite delivery contract. Only the awarding agency can place orders on it.
Was contract 75N95021D00025 competed?
The extent of competition for 75N95021D00025 was full and open competition. The government received 2 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV